A research team has found how a variant in an important epigenetic enzyme — previously associated by population-based genetic studies with Crohn’s disease and other immune disorders — interferes with the action of the innate immune system, potentially upsetting the healthy balance between the microbial population of the gastrointestinal tract and the immune response.